Benefits of EVISTA
In years of research with several clinical trials of more than 37,000 women, EVISTA has shown no increased risk of:
- Uterine cancer
- Ovarian cancer
- Endometrial hyperplasia (uncontrolled cell growth in the uterus)
EVISTA has been prescribed by doctors for over 10 years to help keep bones strong and help prevent spinal fractures due to postmenopausal osteoporosis. EVISTA stops the thinning of the bones, increases bone mineral density, and helps restore the bone turn-over rate (the process of breaking down and rebuilding bone) to normal, premenopausal levels.
Major Study Shows EVISTA Reduces the Risk of Spinal Fractures
In a major clinical study of 7,700 postmenopausal women with osteoporosis, EVISTA was shown to significantly reduce their risk of getting a first spinal fracture. It even reduced the risk of subsequent fractures in postmenopausal women who had already experienced one.
Also Proven to Reduce the Risk of Invasive Breast Cancer in Postmenopausal Women With Osteoporosis
In the same clinical trial of 7,700 postmenopausal women with osteoporosis, EVISTA was proven to have a second benefit — reducing the risk of invasive breast cancer — the most common kind of breast cancer. Additional large studies have confirmed these results.
